STL Volume 28 Number 3

STL Volume 28 Number 3
3 POSTS 0 COMMENTS
Purchase PDF for $2.79
a man with apparent hair loss looking at his reflection in a mirror

The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current...

Oral JAK inhibitors are now the first-line treatment for advanced alopecia areata, surpassing topical JAK inhibitors. Baricitinib's FDA approval in 2022 was a significant milestone. More JAK inhibitors are being studied, and additional medications may gain approval soon. JAK inhibitors show promise for alopecia areata with a generally good safety profile, but long-term data is lacking.
African-American woman with vitiligo closeup, smiling

Utilization of Topical Ruxolitinib in Dermatology: A Review

Topical ruxolitinib shows promise in various dermatological conditions, including atopic dermatitis, vitiligo, psoriasis, and lichen planus, with a favorable safety profile compared to oral JAK inhibitors. However, its effectiveness in alopecia areata remains inconclusive.
Pharmaceutical Worker Examining a Pill, close-up

Update on Drugs & Devices: May – June 2023

Update on Targeted alkali thermolysis (TAT) technology (Brella™ 3-miniute SweatControl Patch™), Retifanlimab-dlwr for IV infusion (Zynyz™), Spesolimab IV for IV infusion (Spevigo®) and CRISPR-based therapy (NTLA-2002).

POPULAR

Advertisement